nach oben

Erschienen in:

01.05.2010 | Original Article

Heterogeneity of epithelial and stromal cells of head and neck squamous cell carcinomas in ex vivo chemoresponse

verfasst von: Iris-Susanne Horn, Gunnar Wichmann, Christian Mozet, Andreas Dietz, Ralph Dollner, Katrin Tschöp, Andreas Boehm

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Valid prediction of the effectiveness of chemotherapeutic agents in individual head and neck squamous cell carcinoma (HNSCC) is desirable and might be achieved using ex vivo assays.

Methods

Three biopsies from each of 15 HNSCC were taken, minced and digested by collagenase. The digested HNSCC was added to serial dilutions of either cisplatin (CIS) or docetaxel (DTX), which were prepared under flavin-protecting conditions in ECM-coated microtiterplates. After 72-h incubation, cultures were methanol-fixed and Giemsa-stained. The cutoff concentration (COC; concentration completely suppressing colony formation) for epithelial cells (EC) and stromal cells (SC) was evaluated.

Results

12/15 HNSCC (80%) were evaluable. Despite significant correlation of COC of CIS in respect of colony formation of EC or SC, no significant differences in response of individual HNSCC specimens were found in the t test for paired samples (p > 0.16). The same applied to DTX. However, EC and SC showed heterogeneity in chemoresponses leading to COC variability of more than one titration step in 44.1% (CIS) and 20% of HNSCC (DTX). No significant correlation between the COC of both cell populations was found in HNSCC specimens.

Conclusions

The ex vivo chemoresponse of EC and SC of HNSCC must be analyzed separately.

Wright JL, Cobb JP, Gumport SL, Golomb FM, Safadi D (1957) Investigation of the relation between clinical and tissue culture response to chemotherapeutic agents of human cancer. N Engl J Med 257:1207–1211PubMedCrossRef

DiPaolo JA, Dowd JE (1961) Evaluation of inhibition of human tumor tissue by cancer chemotherapeutic drugs with an in vitro test. J Natl Cancer Inst 27:807–815PubMed

Courtenay VD, Mills J (1978) An in vitro colony assay for human tumours grown in immune-suppressed mice and treated in vivo with cytotoxic agents. Br J Cancer 37:261–268PubMed

Freeman AE, Hoffman RM (1986) In vivo-like growth of human tumors in vitro. Proc Natl Acad Sci USA 83:2694–2698CrossRefPubMed

Vescio RA, Redfern CH, Nelson TJ, Ugoretz S, Stern PH, Hoffmann RM (1987) In vivo-like drug responses of human tumors growing in three-dimensional, gel-supported, primary culture. Proc Natl Acad Sci USA 84:5029–5033CrossRefPubMed

Vescio RA, Connors KM, Bordin GM, Robb JA, Youngkin T, Umbreit JN, Hoffmann RM (1990) The distinction of small cell and non-small cell lung cancer by growth in native-state histoculture. Cancer Res 50:6095–6099PubMed

Furukawa T, Kubota T, Watanabe M, Takahara T, Yamaguchi H, Kase S, Kodaira S, Ishibiki K, Kitajima M (1992) High in vitro correlation of drug response using sponge-gel-supported three-dimensional histoculture and the MTT end point. Int J Cancer 51:489–498CrossRefPubMed

Robbins KT, Varki NM, Storniolo AM, Hoffman H, Hoffman RM (1991) Drug response of head and neck tumors in native-state histoculture. Arch Otolaryngol Head Neck Surg 117:83–86PubMed

Von Hoff DD (1990) He’s not going to talk about in vitro predictive assays again, is he? J Natl Cancer Inst 82:96–101CrossRef

10.

Dollner R, Granzow C, Werner JA, Dietz A (2004) Is there a role for chemosensitivity tests in head and neck cancer? Onkologie 27:310–315CrossRefPubMed

11.

Weisenthal LM, Lippman ME (1985) Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat Rep 69:615–632PubMed

12.

Dietz A, Rudat V, Dreyhaupt J, Pritsch M, Hoppe F, Hagen R, Pfreundner L, Schröder U, Eckel H, Hess M, Schröder M, Schneider P, Jens B, Zenner HP, Werner JA, Engenhardt-Cabillic R, Vanselow B, Plinkert P, Niewald M, Kuhnt T, Budach W, Flentje M (2009) Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial). Eur Arch Otorhinolaryngol 266(8):1291–1300CrossRefPubMed

13.

Rajaraman R, Guernsey DL, Rajaraman MM, Rajaraman SR (2006) Stem cells, senescence, neosis and self-renewal in cancer. Cancer Cell Int 6:25. doi:10.1186/1475-2867-6-25 CrossRefPubMed

14.

Rajamaran R, Rajaraman MM, Rajaraman SR, Guernsey DL (2005) Neosis: a paradigm of self-renewal in cancer. Cell Biol Int 29:1084–1097CrossRef

15.

Heuser M, Kopun M, Rittgen W, Granzow C (2005) Cytotoxicity determination without photochemical artifacts. Cancer Lett 223:57–66CrossRefPubMed

16.

Granzow C, Kopun M, Kröber T (1995) Riboflavin-mediated photosensitization of Vinca alkaloids distorts drug sensitivity assays. Cancer Res 55:4837–4843PubMed

17.

Wichmann G, Horn I-S, Boehm A, Mozet C, Tschöp K, Dollner R, Dietz A (2009) Single biopsies from head and neck squamous cell carcinomas are representative regarding the entire tumor’s chemosensitivity to cisplatin and docetaxel. Onkologie 32(5):264–272CrossRefPubMed

18.

Dietz A, Tschöp K, Wichmann G, Granzow C (2008) Method and kit for the ex vivo evaluation of the response of a tumor to conditions to be tested. US-Provisional Ser. No. 61/044,082

19.

Cabelguenne A, Blons H, Waziers De I, Carnot F, Houllier A-M, Soussi T, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P (2000) p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol 18:1465–1473PubMed

20.

Fouret P, Temam S, Charlotte F, Lacau-St-Guily J (2002) Tumor stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumor response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck. Br J Cancer 87:1390–1395CrossRefPubMed

21.

Hoffmann TK, Sonkoly E, Hauser U, Lierop A, Whiteside TL, Klussmann JP, Hafner D, Schuler P, Friebe-Hoffmann U, Scheckenbach K, Erjala K, Gréman R, Schipper J, Bier H, Balz V (2008) Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma. Oral Oncol 44(12):1100–1109CrossRefPubMed

22.

Andrews GA, Xi S, Pomerantz RG, Lin CJ, Gooding WE, Wentzel AL, Wu L, Sidransky D, Grandis JR (2004) Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis. Head Neck 26:870–877CrossRefPubMed

23.

American Joint Committee on Cancer: Comparison Guide: Cancer Staging Manual Fifth versus Sixth Edition. http://www.cancerstaging.org/products/ajccguide.pdf. Accessed 31 March 2009

24.

Dollner R, Kopun M, Dietz A, Wiessler M, Granzow C (2002) Chemoreactivity profiling of HNSCC: equipotentiality of platinum compounds and glufosfamide, a novel alkylating agent. Proc Am Assn Cancer Res 43:926–931

25.

Dollner R, Granzow C, Helmke BM, Ruess A, Schad A, Dietz A (2004) The impact of stromal cell contamination on chemosensitivity testing of head and neck carcinoma. Anticancer Res 24:325–331PubMed

26.

Desoize B, Berthiot G, Manot L, Coninx P, Dumont P (1996) Evaluation of a prediction model of cisplatin dose based on total platinum plasma concentration. Eur J Cancer A 32:1734–1738CrossRef

27.

Bissett D, Setanoians A, Cassidy J, Graham MA, Chadwick GA, Wilson P, Auzannet V, Le Bail N, Kaye SB, Kerr DJ (1993) Phase I and pharmakokinetic study of Taxotere (RP 56976) administered as a 24-h infusion. Cancer Res 53:523–527PubMed

28.

Witz IP, Levy-Nissenbaum O (2006) The tumor microenvironment in the post-PAGET era. Cancer Lett 242:1–10CrossRefPubMed

29.

Freeman AE, Hoffman RM (1986) In vivo-like growth of human tumors in vitro. Proc Natl Acad Sci USA 83:2694–2698CrossRefPubMed

30.

Dollner R, Granzow C, Neudert M, Dietz A (2006) Ex vivo chemosensitivity of head and neck carcinoma to cytostatic drug combinations. Anticancer Res 26:1651–1655PubMed

31.

Granzow C, Kopun M, Heuser M, Herth F, Becker HD (2004) Chemoresistance of human lung tumor stromal cells. Am Assn Cancer Res 95th Annual Meeting Proc Suppl. abstract LB-82

32.

Hasegawa Y, Goto M, Hanai N, Ijichi K, Adachi M, Terada A, Hyodo I, Ogawa T, Furukawa T (2007) Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer. Oral Oncol 43:749–756CrossRefPubMed

33.

Singh B, Li R, Xu L, Poluri A, Patel S, Shaha AR, Pfister D, Sherman E, Goberdhan A, Hoffman RM, Shah J (2002) Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 24:437–442CrossRefPubMed

34.

Mukaida H, Hirabayashi N, Hirai T, Iwata T, Saeki S, Toge T (1991) Significance of freshly cultured fibroblasts from different tissues in promoting cancer cell growth. Int J Cancer 48:423–427CrossRefPubMed

35.

Zhang W, Matrisian LM, Holmbeck K, Vick CC, Rosenthal EL (2006) Fibroblast-derived MT1-MMP promotes tumor progression in vitro and in vivo. BMC Cancer 6:52CrossRefPubMed

36.

Rosenthal EL, McCrory A, Talbert M, Carroll W, Magnuson JS, Peters GE (2004) Expression of proteolytic enzymes in head and neck cancer-associated fibroblasts. Arch Otolaryng Head Nack Surg 130:943–947CrossRef

37.

Song Z, Powell WC, Kasahara N, van Bokhoven A, Miller GJ, Roy-Burman P (2000) The effect of fibroblast growth factor 8, isoform b, on the biology of prostata carcinoma cells and their interaction with stromal cells. Cancer Res 60:6730–6736PubMed

Titel: Heterogeneity of epithelial and stromal cells of head and neck squamous cell carcinomas in ex vivo chemoresponse
verfasst von: Iris-Susanne Horn
Gunnar Wichmann
Christian Mozet
Andreas Dietz
Ralph Dollner
Katrin Tschöp
Andreas Boehm
Publikationsdatum: 01.05.2010
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 6/2010
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-009-1124-4

Springer Medizin

Heterogeneity of epithelial and stromal cells of head and neck squamous cell carcinomas in ex vivo chemoresponse